Manipal Health Enterprises IPO - India's Largest Hospital Network Makes Market Debut in July 2026

Manipal Health Enterprises IPO - India's Largest Hospital Network Enters Capital Markets

The Manipal Health Enterprises IPO opens July 29 to 31, 2026, marking the public market debut of India's largest multispecialty hospital network by licensed bed capacity. Manipal Health Enterprises Limited (MHEL) - operating under the brand Manipal Hospitals - is a Bengaluru-headquartered, pan-India healthcare provider with 49 hospitals, 13,037 licensed beds, and 21 clinics across 14 states and union territories as of March 31, 2026.

The IPO raises ₹9,275.22 crore through a combination of a fresh issue of ₹8,000 crore (13.56 crore shares) and an Offer for Sale of ₹1,275.22 crore (2.16 crore shares) at a price band of ₹560 to ₹590 per share. The fresh issue proceeds go primarily towards repaying approximately ₹5,552.76 crore of debt and acquiring the remaining minority stake in this Pune-based hospital group for ₹574 crore.

Manipal Health Enterprises is backed by Temasek (via Imperius Healthcare Investments Pte. Ltd.) and promoted by Dr. Ranjan Ramdas Pai and the Manipal Education and Medical Group (MEMG). The company has grown aggressively through strategic M&A - adding Columbia Asia (2021), Vikram Hospital (2021), AMRI Hospitals (2023), Medica Synergie (2024), and Sahyadri Hospitals (October 2025) to its network. It now surpasses Apollo Hospitals in licensed bed capacity, establishing itself as India's largest private hospital chain by beds.

IPO Details

The issue is priced at ₹560 to ₹590 per share. Retail investors can apply for a minimum of 1 lot (25 shares) at ₹14,750. Read all related documents carefully before making investment decisions.

IPO Date and Timetable

The IPO opens July 29, 2026 and closes July 31. Shares are credited to the demat account on August 4 - one trading day before listing on BSE and NSE on August 5, 2026. Allotment and listing do not happen on the same day.

About Manipal Health Enterprises Limited

Manipal Health Enterprises Limited was incorporated in 2010 and is part of the Manipal Group, founded by T. M. A. Pai. The company operates the Manipal Hospitals network - one of India's most recognised healthcare brands. Headquartered at The Annexe, #98/2, Rustom Bagh, HAL Airport Road, Bengaluru, Karnataka 560017, the company has evolved from a regional hospital operator into India's largest private multispecialty hospital network through a decade of strategic acquisitions and organic growth.

Promoters:

• Imperius Healthcare Investments Pte. Ltd. (Temasek-backed)
• Kabru Investments Pte. Ltd.
• Kangto Investments Pte. Ltd.
• Manipal Global Health Services
• MEMG International Ltd.
• Ranjan Ramdas Pai

Pre-IPO promoter holding: 81.43% | Post-IPO: 72.08%

Workforce (March 31, 2026): 24,240 full-time employees including 11,048 nurses, 6,362 paramedics, and 6,830 administrative staff

Key Accreditations: NABH (National Accreditation Board for Hospitals), AAHRPP, NABL, and Nursing Excellence recognition across network hospitals

Hospital Network and Expansion

As of March 31, 2026, Manipal Health Enterprises operates 49 hospitals with 13,037 licensed beds across 14 states and union territories - the widest hospital footprint among private chains in India (Source: CRISIL Report).

Growth trajectory:

• FY24: 33 hospitals, 9,520 licensed beds
• FY26: 49 hospitals, 13,037 licensed beds
• Between FY21-FY26, added 5,548 beds through M&A alone

Hospital Network Additions (M&A Strategy):

This October 2025 acquisition was funded through ₹5,310 crore in NCDs at a 9% coupon - significantly raising leverage, which the IPO proceeds aim to address.

Geographic Leadership: Manipal Hospitals is the only private hospital chain with leadership positions in three metro markets - Bengaluru, Kolkata, and Pune - while also serving non-metro markets. Key cities include Bengaluru, Pune, Goa, Kolkata, Ranchi, Delhi-NCR, Mysuru, Gurgaon, and others. However, Karnataka contributes 46-60% of revenue, representing meaningful geographic concentration.

Healthcare Services

Manipal Health Enterprises provides a comprehensive range of healthcare services:

• Tertiary and quaternary care
• Organ transplants (kidney, liver, heart, lungs)
• Oncology (cancer care)
• Cardiology and cardiac surgery
• Neurology and neurosurgery
• Orthopaedics
• Outpatient services and diagnostics
• Preventive healthcare
• Medical tourism

The company is a preferred destination for international patients requiring complex, high-acuity interventions.

Financial Performance

Key Financial Highlights:

• Revenue grew 26% in FY26, driven by acquisition-led capacity addition and higher ARPOB
• PAT declined 15% in FY26 to ₹916.52 crore despite revenue growth - due to higher employee costs, finance costs, depreciation, and amortisation from acquisitions
• EBITDA grew 24% YoY to ₹2,795.94 crore in FY26 with a 27.05% margin
• Revenue CAGR FY23-26: 29%; EBITDA CAGR FY23-26: 27% - fastest among major listed hospital chains
• ARPOB (Average Revenue Per Occupied Bed): ₹66,144 per day in FY26 (up from ₹59,820 in FY25) - growing case mix and premium payor quality
• Occupancy rate: 64.47% in FY26 (operational beds: 6,878 of 13,037 licensed) - steady through rapid capacity expansion
• PAT margin: 8.87% (FY26) vs 13.12% (FY25) - margin compression due to acquisition debt servicing
• ROCE: 21.88% (FY26), declining from 27.74% in FY24 as new assets ramp up
• Total borrowings: ₹10,553.43 crore (FY26), up sharply from ₹4,766.83 crore in FY25 following the Pune hospital acquisition debt
• Net Debt to Adjusted EBITDA: approximately 3.74x in FY26 (vs 2.00x in FY25 and 1.09x for Fortis)
• EPS (diluted FY26): ₹6.97 | Post-IPO P/E at ₹590: 84.65x
• RoNW: 10.57% | NAV: ₹72.55

Use of Proceeds

The fresh issue proceeds of ₹8,000 crore will be utilised as follows:

The debt repayment allocation is the single largest use - addressing the NCD-funded Pune hospital acquisition debt. Management has indicated this will make Manipal Hospitals largely debt-free post-listing, which will significantly reduce finance costs and improve PAT margins.

GMP and Allotment Details

• GMP: ₹9 to ₹25 per share (July 27-29, 2026) - an estimated 2-4% premium over ₹590
• GMP trend: High of ₹50 (July 20); moderated to ₹13-25 range by IPO opening - indicating cooling of early grey market enthusiasm
• Lot size: 25 shares (1 lot) at ₹14,750
• Allotment date: August 3, 2026

Investor Allocation:

• QIB: 75% of net offer (11,77,14,612 shares)
• NII: 15% of net offer (2,35,42,922 shares)
• Retail: 10% of net offer (1,56,95,282 shares)
• Employee: 2,80,899 shares (at ₹56 discount)

Note: Retail allocation is only 10% of the net offer (vs the usual 35%) - a common feature of large hospital IPOs where QIBs dominate. Anchor investors committed ₹4,167.10 crore on July 28, 2026 (7.06 crore shares at ₹590).

The GMP is showing cautious sentiment. It is unofficial and unregulated - listing gains cannot be guaranteed.

Peer Comparison

At 84.65x post-IPO P/E, Manipal Health Enterprises is priced at a premium to all three listed peers (Apollo 66x, Max 75x, Fortis 70x; peer average approximately 65-75x). The premium reflects its position as India's largest hospital network by beds, fastest revenue CAGR among the peer group, and post-debt-repayment margin recovery potential. On EV/Adjusted EBITDA basis, the valuation is more comparable at approximately 35x - broadly in line with pan-India hospital chains.

Risks to Consider

PAT Declined Despite Revenue Growth FY26 PAT fell 15% to ₹916.52 crore even as revenue grew 26%. Higher interest and depreciation from the debt-funded Sahyadri acquisition drove this decline. This is a temporary but significant headwind - investors must be comfortable with near-term earnings pressure before the debt repayment impact reflects in financials.

Highly Leveraged Balance Sheet Total borrowings of ₹10,553.43 crore in FY26 with a Net Debt to Adjusted EBITDA ratio of approximately 3.74x is among the highest in the listed hospital peer set. While IPO proceeds address this substantially, residual debt and its servicing cost will continue to weigh on margins until the balance sheet fully normalises.

Geographic Concentration Karnataka accounts for 46-60% of the company's revenue. Regulatory changes, competitive dynamics, or disruptions in Karnataka could disproportionately impact overall performance despite the pan-India footprint.

Occupancy and ARPOB Below Peers The occupancy rate of 64.47% is below listed peer levels of 67-76% (Apollo, Max, Fortis). ARPOB of ₹66,144 per day is below Fortis (₹68,800) and significantly below Max Healthcare (₹77,800). While management views the occupancy gap as a levers for operating leverage improvement, this remains to be demonstrated.

Aggressive Valuation At 84.65x post-IPO P/E, this IPO is priced at a premium to listed peers Apollo, Max, and Fortis, all of which trade at 65-75x earnings. Limited margin of safety at these levels requires the debt repayment and margin recovery thesis to play out as planned.

Sahyadri Integration Risk The recently acquired Pune-based hospital chain was reporting losses at acquisition time. Integration risk remains - if the turnaround takes longer than anticipated, earnings could remain under pressure.

How to Apply for Manipal Health Enterprises IPO

Apply for the Manipal Health Enterprises IPO via Tradejini during the subscription period July 29-31, 2026:

1. Open Tradejini demat account
2. Go to IPO section in Products Menu
3. Select the Manipal Health Enterprises IPO application
4. Enter bid at ₹560 to ₹590 per share, lot size 25 shares (₹14,750)
5. Authorise UPI mandate from your bank account

Employees of Manipal Health Enterprises can apply separately at a discount of ₹56 per share (up to ₹5 lakh per employee application). Complete the IPO application form and read all related documents carefully before investing.

Conclusion

Manipal Health Enterprises Limited is a landmark IPO - the public debut of India's largest hospital network by licensed bed capacity, with 49 hospitals and 13,037 beds across 14 states. The company has delivered the fastest revenue CAGR among major listed hospital chains at 29% over FY23-26 through a disciplined acquisition and integration strategy.

The GMP of ₹9-25 signals a modest 2-4% premium at listing, with earlier excitement having moderated significantly. The IPO is aggressively valued at 84.65x post-IPO P/E - a premium to listed peers Apollo (66x), Fortis (70x), and Max (75x). However, debt repayment from IPO proceeds is expected to materially improve PAT margins post-listing. Key risks include the 15% PAT decline in FY26, elevated leverage at 3.74x Net Debt/EBITDA, Karnataka revenue concentration, and Sahyadri integration execution. Well-informed investors with a medium to long-term horizon may consider this for healthcare sector exposure.

Apply via your Tradejini demat account during the subscription period July 29 to 31, 2026.

Disclaimer: The information provided in our blogs is for informational purposes only and should not be construed as financial, investment, or trading advice. Trading and investing in the securities market carries risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Copyrighted and original content for your trading and investing needs.

© 2026 — Tradejini. All Rights Reserved.